Company Overview - Tiger Med is a clinical research service provider based in Hangzhou, China, established on December 15, 2004, and listed on August 17, 2012. The company specializes in providing professional clinical research services for pharmaceutical and health-related products, covering phases I to IV clinical trials, data management, regulatory submissions, and various medical services [1][7]. Stock Performance - On March 27, Tiger Med's stock rose by 5%, reaching a price of 53.32 CNY per share, with a trading volume of 696 million CNY and a turnover rate of 2.35%. The total market capitalization is 45.91 billion CNY. The stock has experienced a cumulative increase of 6.82% over the past three days [1][7]. Shareholder Insights - E Fund's ChiNext ETF (159915) is among the top ten shareholders of Tiger Med, having reduced its holdings by 1.88 million shares in the third quarter, now holding 11.26 million shares, which represents 1.63% of the circulating shares. The estimated floating profit today is approximately 28.60 million CNY, with a total floating profit of 36.48 million CNY over the past three days [2][8]. Fund Performance - E Fund's ChiNext ETF (159915) has a total asset size of 100.45 billion CNY, with a year-to-date return of 2.38%, ranking 1280 out of 5563 in its category. Over the past year, it has achieved a return of 55.52%, ranking 386 out of 4429, and since inception, it has returned 274.08% [2][8]. Fund Holdings - Six funds under E Fund have significant holdings in Tiger Med, totaling 2.56 million shares. Based on the previous day's closing price of 50.78 CNY, the estimated floating profit today is around 650,660 CNY, with a total floating profit of 829,980 CNY over the past three days [4][10]. Fund Manager Profiles - The fund managers of E Fund's ChiNext ETF (159915) are Cheng Xi and Liu Shurong. Cheng has been in the position for 9 years and 327 days, managing assets totaling 252.07 billion CNY, with the best return during his tenure being 131.04%. Liu has been managing 127.68 billion CNY for 8 years and 255 days, achieving a best return of 194.12% [3][9].